[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_97":98},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","sfbj9rl4t404hq3b50wm3nx7q","revision",2,"title","CalciMedica, Inc. CFO 斯蒂芬·巴丁辞职","originalTitle","CalciMedica, Inc. (0001534133) (Filer)","summary","CalciMedica, Inc. CFO 斯蒂芬·巴丁因寻求其他职业机会于 2026 年 10 月 15 日辞职，将于公司发布 2026 年第三季度财报后生效。其辞职未涉及与公司分歧。","reason","source",{"_11":87,"_88":89,"_90":91,"_92":57,"_93":94,"_95":96},"links",{"_84":85,"_63":86},"publishedAt","2026-10-16T20:46:45.000Z","discoveredAt","2026-10-16T22:50:14.490Z","timelineAt","category","tip","tags",[81,82,83],"stockSymbols",[80],"score",23,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fwhy3hxuESKY",{"_72":73,"_15":74},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","bd0fc8ff-5502-4a8f-830e-489381e3f7ce","CalciMedica CFO 斯蒂芬·巴丁辞职",{"_72":73,"_15":74},"zh","

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2026

CalciMedica, Inc.

(Exact name of Registrant as Specified in Its Charter)

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n	\n	\n
Delaware		001-39538		45-2120079
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n
505 Coast Boulevard South, Suite 300-9
La Jolla, California		92037
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 952-5500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n\n

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n\n

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n\n

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n	\n	\n
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		CALC		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

\n\n\n

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 15, 2026, Stephen Bardin, the Chief Financial Officer, principal accounting officer and principal financial officer of CalciMedica, Inc. (the “Company”), provided notice of his resignation, to be effective immediately following the filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, to pursue another professional opportunity. Mr. Bardin’s resignation was not due to any disagreement with the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n	\n\n	\n	\n\n	\n
\n		\n		\n		CalciMedica, Inc.
\n	\n	\n
Date: October 16, 2026		\n		By:		/s/ A. Rachel Leheny, Ph. D.
\n		\n		Name:		A. Rachel Leheny, Ph. D.
\n		\n		Title:		Chief Executive Officer

","zhKind","complete","CALC","政策与监管","退市","公司与财报","aihot","/items/sfbj9rl4t404hq3b50wm3nx7q","https://www.sec.gov/Archives/edgar/data/1534133/000119312526424203/0001193125-26-424203-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792454400&sig=3dbe6cd67490ee5b","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792454400&sig=28d09d2ec91c5a63 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792454400&sig=4324ec5a457d0f39 96w","changelogVersion","2026-10-01T08:00"]